Prevalence of adverse effects of COVID19 vaccines among a sample of Iranian healthcare workers; a comparison between the three available vaccines in Iran

  • Mohammad Mousavi Dentofacial Deformities Research Center, Research Institute of Dental Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Azita Tehranchi Department of Orthodontics, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Mahshid Namdari Department of Community Oral Health, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Maryam Sadeghipour Department of Community Oral Health, Research Institute of Dental Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Mohsen Dalband Department of Oral and Maxillofacial Surgery, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Mahsa Malek Mohammadi Department of Community Oral Health, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Kazem Dalaie Department of Orthodontics, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Abstract

Objective: Describing what to expect after the first and second dose of vaccination will increase the public confidence. This study aimed to describe the short-term side effects after receiving the first, the second, or both doses of Sputnik V, Oxford-AstraZeneca, and Sinopharm vaccines in personnel and students of shahid Beheshti dentistry school. Methods: A cohort project has been conducting at the dental faculty since June 2020. This article is a cross-sectional study as a section of the cohort project. Dental faculty began its campaign to vaccinate the personnel on April 2021, with the Sputnik V and Oxford-AstraZeneca and Sinopharm. An employed operator phoned each one by one after 48 hours of vaccination. She asked them about any experienced symptoms after receiving each dose. The reported symptoms were coded and categorized. Results: The most common symptoms in AstraZeneca's first dose were fever followed by Myalgia. After the second dose, the frequency of all symptoms had been reduced significantly. After the first dose of Sputnik V, the most common symptoms were Myalgia followed by fever. The frequency of fever and pain at the injection site increased significantly after the second dose (P<.001). In the Sinopharm group, all symptoms occurred whit a low percentage. The most common symptoms were again, Myalgia and pain at the injection site. Conclusion: post-vaccination adverse effects were mild in all groups and controlled by analgesic. Fever, myalgia and pain at the injection site are the most common symptoms reported after vaccination by all three types of vaccines
 
share this Article by

References

1. Meo S, Bukhari I, Akram J, Meo A, Klonoff D. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci. 2021;25(3):1663-9.
2. Ghiasi N, Arabsorkhi M, Hoseyni T, Esfandiari K, Sadighpour T, Jahantigh H. Efficacy and side effects of Sputnik V, Sinopharm and AstraZeneca vaccines to stop COVID-19; a review and discussion. Immunopathologia Persa. 2021;7(2):31.
3. Metcalf CJE, Ferrari M, Graham AL, Grenfell BT. Understanding herd immunity. Trends in immunology. 2015;36(12):753-5.
4. Lippi G, Mattiuzzi C, Henry BM. Mild Adverse Reactions after COVID-19 Vaccination: Updated Analysis of Italian Medicines Agency Data. Available at SSRN 3817988. 2021.
5. Doroftei B, Ciobica A, Ilie O-D, Maftei R, Ilea C. Mini-review discussing the reliability and efficiency of COVID-19 vaccines. Diagnostics. 2021;11(4):579.
6. Baraniuk C. Covid-19: What do we know about Sputnik V and other Russian vaccines? bmj. 2021;372.
7. Raadsen M, Du Toit J, Langerak T, van Bussel B, van Gorp E, Goeijenbier M. Thrombocytopenia in virus infections. Journal of Clinical Medicine. 2021;10(4):877.
8. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. The Lancet. 2020;396(10267):1979-93.
9. Song BJ, Katial RK. Update on side effects from common vaccines. Current allergy and asthma reports. 2004;4(6):447-53.
10. Saeed BQ, Al-Shahrabi R, Alhaj SS, Alkokhardi ZM, Adrees AO. Side effects and perceptions following Sinopharm COVID-19 vaccination. International Journal of Infectious Diseases. 2021;111:219-26.
11. El-Shitany NA, Harakeh S, Badr-Eldin SM, Bagher AM, Eid B, Almukadi H, et al. Minor to moderate side effects of Pfizer-BioNTech COVID-19 vaccine among Saudi residents: A retrospective cross-sectional study. International journal of general medicine. 2021;14:1389.
12. Alhazmi A, Alamer E, Daws D, Hakami M, Darraj M, Abdelwahab S, et al. Evaluation of Side Effects Associated with COVID-19 Vaccines in Saudi Arabia. Vaccines. 2021;9(6):674.
13. Abu-Hammad O, Alduraidi H, Abu-Hammad S, Alnazzawi A, Babkair H, Abu-Hammad A, et al. Side Effects Reported by Jordanian Healthcare Workers Who Received COVID-19 Vaccines. Vaccines. 2021;9(6):577.
14. Joshi U, Singh P. Adverse reaction following COVISHEILD a covid 19 vaccine-Experience of from a single Centre.
15. Hatmal MmM, Al-Hatamleh MA, Olaimat AN, Hatmal M, Alhaj-Qasem DM, Olaimat TM, et al. Side Effects and Perceptions Following COVID-19 Vaccination in Jordan: A Randomized, Cross-Sectional Study Implementing Machine Learning for Predicting Severity of Side Effects. Vaccines. 2021;9(6):556.
16. Hervé C, Laupèze B, Del Giudice G, Didierlaurent AM, Da Silva FT. The how’s and what’s of vaccine reactogenicity. npj Vaccines. 2019;4(1):1-11.
17. Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine after Effects and Post-Vaccine Infection in a Real World Setting: Results from the COVID Symptom Study App. 2021.
18. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet. 2020;396(10249):467-78.
19. Silveira MM, Moreira GMSG, Mendonça M. DNA vaccines against COVID-19: Perspectives and challenges. Life sciences. 2020:118919.
20. Abbood, Muhanad Hadi; HASSAN, Jabbar Sirhan; MEHAMMED, Aqeel Jassim. Case study of COVID 19 from August to end of December 2020 in Babylon, Iraq. Iraq Medical Journal, v. 5, n. 3, sep. 2021
21. Control CfD, Prevention. Possible side effects after getting a COVID-19 vaccine. 2021.
22. Al-khayat, Zakarea Abdullah Yaseen et al. Single Center Study of Vaccination Breakthrough infection with SARS-CoV-2 Among Erbil Population in August 2021. Journal of Contemporary Medical Sciences, v. 7, n. 5, oct. 2021.
Published
2021-12-26
How to Cite
MOUSAVI, Mohammad et al. Prevalence of adverse effects of COVID19 vaccines among a sample of Iranian healthcare workers; a comparison between the three available vaccines in Iran. Journal of Contemporary Medical Sciences, [S.l.], v. 7, n. 6, dec. 2021. ISSN 2413-0516. Available at: <http://www.jocms.org/index.php/jcms/article/view/1121>. Date accessed: 25 jan. 2022. doi: https://doi.org/10.22317/jcms.v7i6.1121.